A substantial body of experimental and clinical evidence supports the effectiveness of intranasal insulin in treating chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, mild cognitive impairment, and neuropathy (9–11). The gene discussed is INS; the disease is Cognitive impairment.